Study of T-DM1 vs Herceptin, post surgery for HER2+ Breast Cancer

• Research type

  Research Study

• Full title

  A RANDOMIZED, MULTICENTRE, OPEN LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE RESIDUAL TUMOUR PRESENT PATHOLOGICALLY IN THE BREAST OR AXILLARY LYMPH NODES FOLLOWING PREOPERATIVE THERAPY

• IRAS ID

  109258

• Sponsor organisation

  F Hoffmann-La Roche Ltd

• Eudract number

  2012-002018-37

• ISRCTN Number

  No number provided

• Clinicaltrials.gov Identifier

  No number provided

• Research summary

  Permission to publish Research Summary refused at the request of the researcher

• REC name

  London - Brighton & Sussex Research Ethics Committee

• REC reference

  12/LO/1981

• Date of REC Opinion

  22 Jan 2013

• REC opinion

  Further Information Favourable Opinion